Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSphere Medical Holding Regulatory News (SPHR)

  • There is currently no data for SPHR

Scope Extension to include Manufacturing

23 Nov 2011 07:00

RNS Number : 5845S
Sphere Medical Holding plc
23 November 2011
 



 

23 November 2011

Sphere Medical Holding plc

EN ISO13485 Scope Extension to include Manufacturing

 

 

Cambridge, UK, 23 November 2011: Sphere Medical Holding plc (AIM:SPHR.L) ("Sphere Medical" or the "Company"), a leading developer of innovative patient monitoring and diagnostic products for the critical care market, is pleased to announce that it has received formal certification by its Notified Body, TÜV SÜD Product Service GmbH, of the extension of its existing EN ISO13485 for Design and Development to include production of Medical Monitoring Systems.

This extension now enables Sphere Medical to manufacture its monitoring and diagnostic medical devices, including its Proxima disposable patient-attached arterial blood analyser, at its manufacturing facility in Harston, Cambridge.

Commenting on the EN ISO13485 scope extension, Chief Executive Officer, Dr Stuart Hendry, said:

"The successful completion of the audit and certification by TÜV SÜD, our notified body, validates the excellent quality management system which we have at Sphere Medical. This scope extension is an important achievement and underpins our capability for commercial manufacture at our Harston facility."

 

For further information, please contact:

 

Sphere Medical Holding plc Tel: +44 (0)1223 875222

Dr Stuart Hendry, Chief Executive Officer

Matthew Hall, Chief Financial Officer

 

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Dr Vijay Barathan

 

Buchanan Communications Tel: +44 (0) 20 7466 5000

Tim Anderson

Lisa Baderoon

 

www.spheremedical.com 

 

Notes for Editors

Sphere Medical is a UK based medical device company completing the development of a range of monitoring and diagnostic products designed to provide significant improvements in patient management in a number of hospital specialities. Sphere Medical's products are expected to allow near real time measurement of blood gases, various electrolytes and drug levels with laboratory accuracy, at the patient's bedside. This information can be used in a wide range of medical applications and is intended to enable faster clinical decision making and consequently to improve the management of patients.

Sphere Medical's two most advanced products, based on its proprietary microanalyser platform technology, are a disposable patient-attached arterial blood analyser for use in the Intensive Care Unit and Operating Room ('Proxima') and a device for continuous blood monitoring in the bypass circuit in patients undergoing cardiopulmonary bypass surgery ("CPB device"). Sphere Medical has also developed and is selling a device ('Pelorus 1000') that can measure blood levels of the intravenously administered anaesthetic drug, propofol. In each case, these products will ultimately target patients requiring close monitoring and frequent levels of blood testing.

Sphere Medical employs 43 staff in the areas of research and development, product development, sales and marketing and management and operations at its premises at Harston, Cambridge, UK.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXFAAFFFFFF
Date   Source Headline
18th Jul 201311:17 amRNSTR-1: Notification of Major Interest in Shares
17th Jul 20135:20 pmRNSTR-1: Notification of Major Interest in Shares
17th Jul 20134:36 pmRNSTR-1: Notification of Major Interest in Shares
17th Jul 20133:14 pmRNSTR-1: Notification of Major Interest in Shares
17th Jul 20138:01 amRNSDirector/PDMR Shareholding
16th Jul 201312:00 pmRNSResult of General Meeting
16th Jul 20137:00 amRNSResult of Open Offer
8th Jul 20137:00 amRNSPositive results from Proxima technology
1st Jul 20137:00 amRNSPosting of Shareholder Circular
28th Jun 20134:08 pmRNS2012 Annual Report & Accounts and Notice of AGM
28th Jun 20131:13 pmRNSFinal Results for the year ended 31 December 2012
28th Jun 20131:04 pmRNSProposed Collaboration Agreement and Fundraising
4th Dec 20122:40 pmRNSTR-1: Notification of Major Interest in Shares
23rd Nov 20127:00 amRNSPositive Results from Pelorus 1500 Study
25th Sep 20129:30 amRNSPresenting at Proactive Investors Investor Forum
20th Sep 20127:00 amRNSInterim Results 2012
29th Aug 20127:00 amRNSNotice of Interim Results
16th Jul 20127:00 amRNSPelorus 1500 IVD Achieves CE Marking
10th Jul 20127:00 amRNSFirst Sales Order from Sorin for CPB Product
21st Jun 20127:00 amRNSSphere Appoints Distributor in Japan
29th May 20122:29 pmRNSResult of Annual General Meeting
21st May 20127:00 amRNSGrant of Options and Directors' Interests
21st May 20127:00 amRNSGrant of Share Options and Directors' Interests
8th May 20127:00 amRNS2011 Annual Report & Accounts and Notice of AGM
22nd Mar 20127:00 amRNSPreliminary Results
24th Feb 20127:00 amRNSNotice of Preliminary Results
8th Feb 20127:00 amRNSImproving Accuracy of Propofol Dosing
5th Jan 20121:13 pmRNSAmended Notice of Interest in Shares
19th Dec 20117:00 amRNSProxima Generation 2 Achieves European CE Marking
13th Dec 20113:51 pmRNSNotification of Major Interest in Shares
23rd Nov 20117:00 amRNSScope Extension to include Manufacturing
22nd Nov 20113:10 pmRNSNotice of Interest in Shares
21st Nov 201112:49 pmRNSNotice of Interest in Shares
21st Nov 20117:00 amRNSNotification of Major Interest in Shares
21st Nov 20117:00 amRNSClinical Trial Success
18th Nov 20118:40 amRNSCompleted Second Admission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.